This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

A look at the interim results from the P2 trial evaluating darovasertib(IDE196) and crizotinib synthetic lethal combination in metastatic uveal melanoma patients

Ticker(s): IDYA, PFE, IMCR

Who's the expert?

Institution: Keystone Retina Associates

  • Board-certified ophthalmologist specializing in complex vitreo retinal surgery and medical retinal conditions
  • Manages 600 patients with wet-AMD, 250 patients with presbyopia, and 500 patients with geograpgic atrophy.
  • An accomplished clinician, published author, researcher, lecturer, and investigator in national clinical trials studying new therapies for macular degeneration, diabetic macular edema, and retinal vein occlusion. .

Interview Goal
see title. 

Do you want answers to these questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.